Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28932953 | 0.87 | MAPT (0.53) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL7888936 | 0.87 | MAPT (0.53) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL6597766 | 0.85 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL6592432 | 0.84 | TLR2 (0.44) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL6592795 | 0.83 | ALDH1A1 (0.49) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL17386220 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL3741023 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL3739339 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL18831798 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL5805888 | 0.77 | MAPT (0.54) | PDE4BPDE4APDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189883-B1 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6548533-B2 | Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-04-15 | — | — | US | disclosed |
| US-20020094994-A1 | Substituted pyrrolidines | AVENTIS PHARMA LIMITED (GB) | 2002-07-18 | — | — | US | disclosed |
| EP-1189883-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | Aventis Pharma Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000068195-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094994-A1 | Substituted pyrrolidines | VCAM1, ITGB1, ITGA1 | PDE4B 3593/4885PDE4A 3494/4885PDE4C 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.